AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that its Board Chairman, Gabriele Cerrone, has acquired an additional 100,000 ACUT shares through open market purchases. Following this transaction, Cerrone's total shareholding has increased to 4,719,957 shares.
AccuStem Sciences (OTCQB: ACUT), una compagnia di diagnostica in fase clinica focalizzata sui risultati per i pazienti affetti da cancro, ha annunciato che il suo presidente del consiglio, Gabriele Cerrone, ha acquisito ulteriori 100.000 azioni ACUT mediante acquisti sul mercato aperto. A seguito di questa transazione, il totale delle azioni in possesso di Cerrone è aumentato a 4.719.957 azioni.
AccuStem Sciences (OTCQB: ACUT), una empresa de diagnóstico en etapa clínica centrada en los resultados de pacientes con cáncer, ha anunciado que su presidente de la junta, Gabriele Cerrone, ha adquirido 100,000 acciones de ACUT a través de compras en el mercado abierto. Tras esta transacción, la participación total de Cerrone ha aumentado a 4,719,957 acciones.
AccuStem Sciences (OTCQB: ACUT), 암 환자의 결과에 초점을 맞춘 임상 단계 진단 회사가 Gabriele Cerrone 이사장이 추가로 100,000 ACUT 주식을 공개 시장에서 구매했다고 발표했습니다. 이 거래 후, Cerrone의 총 주식 보유량은 4,719,957 주식으로 증가했습니다.
AccuStem Sciences (OTCQB: ACUT), une entreprise de diagnostic en phase clinique axée sur les résultats des patients atteints de cancer, a annoncé que son président du conseil, Gabriele Cerrone, a acquis 100 000 actions ACUT par le biais d'achats sur le marché libre. Suite à cette transaction, la participation totale de Cerrone s'élève à 4 719 957 actions.
AccuStem Sciences (OTCQB: ACUT), ein Unternehmen für klinische Diagnostik, das sich auf die Ergebnisse von Krebspatienten konzentriert, hat angekündigt, dass sein Vorsitzender Gabriele Cerrone zusätzlich 100.000 ACUT-Aktien durch Käufe auf dem freien Markt erworben hat. Nach dieser Transaktion beträgt Cerrones gesamter Aktienbesitz nun 4.719.957 Aktien.
- Chairman's increased stake demonstrates confidence in company
- Significant insider ownership with Chairman holding over 4.7M shares
- Company still trades on OTCQB market rather than major exchange
LONDON and PHOENIX, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 100,000 ACUT shares in the open market. This brings his total holding to 4,719,957 shares.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.
Investor and Media Contact:
Wendy Blosser
Email: investors@accustem.com
FAQ
How many ACUT shares did AccuStem's Chairman purchase in January 2025?
What is the total number of ACUT shares held by Chairman Gabriele Cerrone?
What stock exchange does AccuStem Sciences (ACUT) trade on?
What type of company is AccuStem Sciences (ACUT)?
